See more : Moringa Acquisition Corp (MACA) Income Statement Analysis – Financial Results
Complete financial analysis of Strongbridge Biopharma plc (SBBP) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Strongbridge Biopharma plc, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Sinopec Kantons Holdings Limited (0934.HK) Income Statement Analysis – Financial Results
- Murray International Trust PLC (MYI.L) Income Statement Analysis – Financial Results
- Montana Exploration Corp. (ATDEF) Income Statement Analysis – Financial Results
- Banneker, Inc. (BANI) Income Statement Analysis – Financial Results
- Nippon Television Holdings, Inc. (9404.T) Income Statement Analysis – Financial Results
Strongbridge Biopharma plc (SBBP)
About Strongbridge Biopharma plc
Strongbridge Biopharma plc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs. The company offers Keveyis, an oral carbonic anhydrase inhibitor for treating hyperkalemic, hypokalemic, and related variants of primary periodic paralysis in the United States. Its clinical-stage product candidates include Recorlev, a cortisol synthesis inhibitor, which is in a Phase III clinical trials that for the treatment of endogenous Cushing's syndrome; and Veldoreotide, a somatostatin analog that completed Phase II clinical trial for the treatment of acromegaly. The company was formerly known as Cortendo plc and changed its name to Strongbridge Biopharma plc in September 2015. Strongbridge Biopharma plc was founded in 1996 and is headquartered in Trevose, Pennsylvania.
| Metric | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 30.73M | 21.71M | 18.03M | 7.05M | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 2.21M | 3.82M | 3.99M | 1.48M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 28.52M | 17.89M | 14.04M | 5.56M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 92.80% | 82.40% | 77.89% | 78.95% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 25.80M | 30.90M | 25.44M | 17.27M | 20.02M | 20.14M | 5.84M | 2.53M |
| General & Administrative | 40.87M | 45.81M | 63.34M | 36.29M | 14.88M | 22.72M | 4.59M | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 40.87M | 45.81M | 63.34M | 36.29M | 14.88M | 22.72M | 4.59M | 0.00 |
| Other Expenses | 5.02M | 5.02M | 7.19M | 5.02M | 0.00 | 0.00 | 0.00 | -7.73M |
| Operating Expenses | 71.68M | 81.74M | 95.96M | 58.58M | 34.90M | 42.85M | 10.43M | -5.19M |
| Cost & Expenses | 73.90M | 85.56M | 99.95M | 60.07M | 34.90M | 42.85M | 10.43M | 5.19M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 1.00K | 25.00K | 0.00 | 0.00 |
| Interest Expense | 1.34M | 0.00 | 12.52M | 4.31M | 20.00K | 3.00K | 0.00 | 0.00 |
| Depreciation & Amortization | 5.11M | 5.10M | 7.23M | 5.03M | 10.00K | 11.00K | 6.00K | 3.00K |
| EBITDA | -38.65M | -42.58M | 52.14M | -102.37M | -51.21M | -44.02M | -10.14M | -5.39M |
| EBITDA Ratio | -125.76% | -196.13% | 289.21% | -1,452.84% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -43.17M | -63.85M | -81.92M | -53.02M | -34.90M | -42.85M | -10.43M | -5.19M |
| Operating Income Ratio | -140.46% | -294.05% | -454.45% | -752.47% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -1.93M | 16.16M | 114.31M | -58.69M | -16.46M | -1.23M | 282.00K | -288.00K |
| Income Before Tax | -45.09M | -47.68M | 32.39M | -111.71M | -51.36M | -44.08M | -10.15M | -5.48M |
| Income Before Tax Ratio | -146.72% | -219.62% | 179.66% | -1,585.47% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -15.00K | 1.77M | 536.00K | 1.77M | -2.64M | -450.00K | -480.00K | -93.00K |
| Net Income | -45.08M | -49.45M | 31.85M | -113.48M | -48.60M | -43.58M | -9.67M | -5.30M |
| Net Income Ratio | -146.68% | -227.76% | 176.68% | -1,610.60% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.80 | -0.89 | 0.64 | -3.11 | -2.26 | -2.62 | -0.96 | -0.88 |
| EPS Diluted | -0.80 | -0.89 | 0.64 | -3.11 | -2.24 | -2.62 | -0.96 | -0.88 |
| Weighted Avg Shares Out | 56.11M | 55.38M | 49.72M | 36.54M | 21.55M | 16.61M | 10.11M | 6.02M |
| Weighted Avg Shares Out (Dil) | 56.11M | 55.38M | 49.72M | 36.54M | 21.66M | 16.61M | 10.11M | 6.02M |
Xeris Pharmaceuticals Completes Acquisition of Strongbridge Biopharma
CHICAGO--(BUSINESS WIRE)--Xeris Pharmaceuticals, Inc. (“Xeris”), a pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable drug formulations, today announced that it has successfully completed the previously announced acquisition of Strongbridge Biopharma plc (Nasdaq: SBBP) (“Strongbridge”)....
Strongbridge Biopharma plc Announces Completion of Acquisition by Xeris Pharmaceuticals, Inc.
DUBLIN, Ireland and TREVOSE, Pa., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc (NASDAQ: SBBP) (the “Company” or “Strongbridge”) today announced that the High Court of Ireland (the "Court") has approved the previously announced proposed acquisition of Strongbridge by Xeris Pharmaceuticals,...
Strongbridge Biopharma plc Announces Court Hearing Date to Approve Proposed Acquisition by Xeris Pharmaceuticals, Inc.
DUBLIN, Ireland and TREVOSE, Pa., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc (NASDAQ: SBBP) (the “Company” or “Strongbridge”) today announced that the High Court of Ireland (the “Court”) has set the date of the final court hearing to sanction the...
Strongbridge Biopharma plc Announces Shareholder Approval of Proposed Acquisition by Xeris Pharmaceuticals, Inc.
DUBLIN, Ireland and TREVOSE, Pa., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc (NASDAQ: SBBP) (the “Company” or “Strongbridge”) today announced that its shareholders have voted to approve the previously announced proposed acquisition of Strongbridge by Xeris Pharmaceuticals, Inc. (NASDAQ: XERS)...
Second Leading Independent Proxy Advisory Firm Glass Lewis Recommends Strongbridge Biopharma plc Shareholders Vote “FOR” the Transaction With Xeris
Glass Lewis Joins ISS in Recommending Strongbridge Shareholders Vote “FOR” Transaction with Xeris
Leading Independent Proxy Advisory Firm ISS Recommends Strongbridge Biopharma plc Shareholders Vote “FOR” the Transaction With Xeris
Strongbridge Urges Shareholders to Vote “FOR” All Transaction-Related Proposals Strongbridge Urges Shareholders to Vote “FOR” All Transaction-Related Proposals
Strongbridge Biopharma (SBBP) Reports Q2 Loss, Tops Revenue Estimates
Strongbridge Biopharma (SBBP) delivered earnings and revenue surprises of 20.00% and 13.69%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Strongbridge Biopharma plc Reports Second Quarter 2021 Financial Results and Provides Corporate Update
~ Reports KEVEYIS ® (dichlorphenamide) Second Quarter 2021 Revenue of $10.0 Million, a 28 Percent Increase Compared to $7.8 Million of Revenue During Second Quarter of 2020 ~
Strongbridge Biopharma plc Announces Commencement of Mailing of Proxy Statement
DUBLIN, Ireland and TREVOSE, Pa., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP) (“Strongbridge”), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced for...
Strongbridge Biopharma plc Provides Announcement Under the Irish Takeover Rules for Relevant Securities in Issue
DUBLIN, Ireland and TREVOSE, Pa., July 29, 2021 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP) (“Strongbridge”), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced in...
Source: https://incomestatements.info
Category: Stock Reports